Vivatides Therapeutics

Stub active Updated Apr 13, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location Suzhou, China / Boston, Massachusetts
Founded 2025
Latest Stage Series A
Total Raised $54M
Website https://www.vivatides.com
Sector
biotech therapeutics

Investors

qiming-venture-partners series-a (2026)
highlight-capital series-a (2026)
tf-capital series-a (2026)
apricot-capital series-a (2026)

Founders

Keming Zhou Founder

About

Vivatides Therapeutics is a global biotechnology company focused on developing extrahepatic RNA-targeting therapeutics 1. Founded in 2025, the company has built a differentiated delivery platform spanning both siRNA and antisense oligonucleotides (ASO), with capabilities in ligand conjugation, delivery efficiency, tissue targeting specificity, and safety 1. The company is headquartered in Suzhou, China with operations in Boston 1.

Funding History

Date Round Amount Lead Co-investors
2026-04-10 Series A $54M Qiming Venture Partners Highlight Capital, TF Capital, Apricot Capital 1

What Investors Say

No verified investor quotes available at this time.

What Founders Say

No verified founder quotes available at this time.

Sources

  1. PR Newswire, “Vivatides Therapeutics Announces Oversubscribed $54 Million Series A Financing to Accelerate Extrahepatic RNA Therapeutics Development,” April 10, 2026. https://www.prnewswire.com/news-releases/vivatides-therapeutics-announces-oversubscribed-54-million-series-a-financing-to-accelerate-extrahepatic-rna-therapeutics-development-302738127.html↩↩↩↩